Why Is Portage Biotech Stock Skyrocketing Friday?
The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine mesothelioma animal model.
Mesothelioma is a rare and aggressive cancer that develops in the thin tissue lining the lungs, abdomen, heart or testicles, strongly linked to asbestos exposure.
Also Read: Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
Immunohistochemistry of the tumors revealed a significant infiltration of CD3 and CD45 positive immune effector cells.
According to the company, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor.
Portage is making preparations to commence a first-in-human clinical trial with PORT-7.
In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor.
Portage’s plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial.
This will mark the first time two highly selective A2A and A2B antagonists are combined in patients to achieve a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment.
This innovative approach is designed to fully neutralize adenosine-mediated immune suppression, enhance antitumor responses and broaden the impact of immunotherapy in solid tumors.
In
iOx specializes in developing liposomal iNKT agonists, with its lead candidate, PORT-2, showing encouraging early clinical results.
PRTG Price Action:
Read Next:
- Why Is Milestone Pharmaceuticals Stock Plunging Today?
Photo: Shutterstock
close
Why Is Portage Biotech Stock Skyrocketing Friday?
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
Chevron Sells 70% Interest in East Texas Gas Assets for $525 Million
MT Newswires - 26 minutes ago
-
Johnson & Johnson Faces Setback as Bankruptcy Court Denies Talc Settlement Plan
MT Newswires - 27 minutes ago
-
Grupo Aeroportuario del Pacifico Unit Extends Maturity of $60 Million Credit Line
MT Newswires - 36 minutes ago
-
United Microelectronics Launches Singapore Fab Facility
MT Newswires - 40 minutes ago
-
Samsung Elec appoints mobile chief as interim head of consumer and mobile division
Reuters - 42 minutes ago
-
Samsung Elec appoints mobile chief as interim head of consumer and mobile division
Reuters - 44 minutes ago
-
LG Energy Solution unit to pay $2 bln for Michigan battery venture with GM
Reuters - 49 minutes ago
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
